Drug Profile
Research programme: anti neural cell adhesion molecule L1 antibodies - Elthera
Alternative Names: Anti-L1CAM antibodies - Elthera; L1CAM-targeting therapies - EltheraLatest Information Update: 27 Apr 2023
Price :
$50
*
At a glance
- Originator German Cancer Research Center
- Developer Elthera
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer; Colorectal cancer; Lung cancer; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 27 Apr 2023 Anti neural cell adhesion molecule L1 antibodies are still in preclinical development for Ovarian cancer in Switzerland (Elthera Pipeline, April 2023)
- 27 Apr 2023 Anti neural cell adhesion molecule L1 antibodies are still in preclinical development for Pancreatic cancer in Switzerland (Elthera Pipeline, April 2023)
- 27 Apr 2023 Preclinical trials in Breast cancer in Switzerland (Parenteral) (before April 2023) (Elthera Pipeline, April 2023)